tirzepatide filing Eli Lilly gets nod to launch weight-loss drug in Hong Kong Lilly holds off on tirzepatide
Description
17 , 22 Thus, these two hormones could work together in T2DM as the consistent glucose-lowering effect of GLP-1 could potentiate the role of GIP, whose action is dependent upon the glycemic status
The SURMOUNT-1 clinical trial showed that participants on 15 mg of tirzepatide lost an average of 22.5% of their body weight over 72 weeks
For all completed trials, the primary objective of tirzepatide was found to be superior to the comparator
But the margin for error shrinks dramatically
.webp)
This was followed by a formal FDA warning letter issued January 16, 2026
